Thus, this comparison included (i) trastuzumab/HER2 testing for targeted oncology therapy, (ii) HLA-B*15:02 screening for PGx testing, and (iii) congenital hypothyroidism screening for newborn screening. Here, ERBB2 is linked to congenital hypothyroidism.